[HTML][HTML] BRCA mutations in ovarian and prostate cancer: bench to bedside
Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
[HTML][HTML] Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Y Chen, Q Zhou, W Hankey, X Fang, F Yuan - Cell Death & Disease, 2022 - nature.com
Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …
[HTML][HTML] Improved outcomes with enzalutamide in biochemically recurrent prostate cancer
SJ Freedland, M de Almeida Luz… - … England Journal of …, 2023 - Mass Medical Soc
Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …
Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management
JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
[HTML][HTML] Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in …
Context The prognostic importance of local failure after definitive radiotherapy (RT) in
National Comprehensive Cancer Network intermediate-and high-risk prostate cancer (PCa) …
National Comprehensive Cancer Network intermediate-and high-risk prostate cancer (PCa) …
Targeting sex steroid biosynthesis for breast and prostate cancer therapy
M Poutanen, M Hagberg Thulin, P Härkönen - Nature Reviews Cancer, 2023 - nature.com
Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …
by Poutanen et al. describes the development of treatments for these cancer types that act to …
Clinically localized prostate cancer: AUA/ASTRO guideline. Part III: principles of radiation and future directions
JA Eastham, GB Auffenberg, DA Barocas… - Journal of …, 2022 - journals.lww.com
Purpose: The summary presented herein represents Part III of the three-part series
dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing …
dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing …
[HTML][HTML] Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final …
Background Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or
enzalutamide added at the start of androgen deprivation therapy improves outcomes for …
enzalutamide added at the start of androgen deprivation therapy improves outcomes for …
[HTML][HTML] The Lancet Commission on prostate cancer: planning for the surge in cases
Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
and accounts for 15% of cancers. In this Commission, we report projections of prostate …